Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, is ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable futur ...

SHANGHAI, China and MORRISVILLE, NC, USA I 18, 2024 I Inceptor Bio, a leading innovator in cell therapy, and GRIT Bio, a clinical-stage immunotherapy ...

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

Also, it reversed many pathways of immune suppression exacerbated by obesity and corrected increased tumor development in ...